Compare SFM & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFM | NUVL |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 7.8B |
| IPO Year | 2013 | 2021 |
| Metric | SFM | NUVL |
|---|---|---|
| Price | $79.41 | $95.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $110.55 | ★ $135.33 |
| AVG Volume (30 Days) | ★ 2.7M | 441.5K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.60 | N/A |
| EPS | ★ 5.31 | N/A |
| Revenue | ★ $8,806,159,000.00 | N/A |
| Revenue This Year | $9.03 | N/A |
| Revenue Next Year | $7.40 | $1,064.25 |
| P/E Ratio | $15.41 | ★ N/A |
| Revenue Growth | ★ 14.08 | N/A |
| 52 Week Low | $64.75 | $55.54 |
| 52 Week High | $182.00 | $113.02 |
| Indicator | SFM | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 54.36 | 37.55 |
| Support Level | $76.51 | $73.22 |
| Resistance Level | $82.28 | $107.13 |
| Average True Range (ATR) | 3.16 | 3.37 |
| MACD | 0.30 | -0.48 |
| Stochastic Oscillator | 42.25 | 10.33 |
Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.